A powder formulation for use in a dry powder inhaler, the powder comprises: i) from 0.5 to 5.0 percent by weight of microparticles consisting of an active ingredient that belongs to the long-acting beta2 agonist class of concentration of low dosage having a therapeutic therapeutic dose equal ...
E.MorcilloingentaconnectFundamental & Clinical PharmacologyRamon M, Juan G, Ciscar MA, Marti-Bonmati E, Morcillo EJ, Marin J. Influence of low temperature on bronchodi- latation induced by terbutaline administered by metered dose or dry powder inhalers in asthmatics. Fundam Clin Pharmacol. 2000...
PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS, WHICH UNDERSTAND A LOW-DOSAGE ACTIVE INGREDIENT The invention provides a formulation to be administered as a dry powder for inhalation, suitable for the effective administration of low dose potent active ingredients in the lower respiratory tract of ...
For the HFA MDI dose proportional increases in FP AUC were seen in healthy subjects and asthmatics. In healthy subjects systemic exposure from the HFA MDI was 30% lower than exposure from the CFC MDI resulting in significantly less effect on serum cortisol. In asthmatics systemic exposure to...
Switching to low-global warming potential (GWP) propellants for pressurized metered dose inhalers (pMDIs) is crucial in current inhalation product development, as it is crucial to safeguard patient access. This paper provides both theoretical and experimental evidence to advance the understanding of ...